| Record ID | marc_openlibraries_sanfranciscopubliclibrary/sfpl_chq_2018_12_24_run04.mrc:211258130:3339 |
| Source | marc_openlibraries_sanfranciscopubliclibrary |
| Download Link | /show-records/marc_openlibraries_sanfranciscopubliclibrary/sfpl_chq_2018_12_24_run04.mrc:211258130:3339?format=raw |
LEADER: 03339cam a2200553 i 4500
001 701242603
003 OCoLC
005 20151005093745.0
008 110203s2011 ilua b 001 0 eng c
010 $a2011004666
016 7 $a015895578$2Uk
020 $a9780226359182
020 $a0226359182
035 $a701242603
035 $a(OCoLC)701242603
040 $aICU/DLC$erda$beng$cDLC$dYDX$dYDXCP$dUKMGB$dVP@$dCOO$dCDX$dPUL$dBDX$dSHH$dSFR$dUtOrBLW
042 $apcc
043 $an-us---
049 $aSFRA
050 00 $aHD9999.B444$bH85 2011
082 00 $a338.7/66060973$222
092 $a338.766$bH8747g
100 1 $aHughes, Sally Smith.
245 10 $aGenentech :$bthe beginnings of biotech /$cSally Smith Hughes.
260 $aChicago :$bUniversity of Chicago Press,$c2011.
300 $axv, 213 p. :$bill. ;$c24 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
490 1 $aSynthesis
504 $aIncludes bibliographical references and index.
505 0 $a1. Inventing recombinant DNA technology ; Two scientists on converging paths ;The collaboration ; Patenting and politics ; Steps toward commercialization -- 2. Creating Genentech ; Bob Swanson ; Founding Genentech ; Legal and political obstacles ; A full business plan -- 3. Proving the technology ; A portentous experiment ; Switching targets ; Negotiating research agreements -- Making somatostatin ; Wider issues -- 4. Human insulin: Genentech makes its mark ; Seeking corporate contracts; Procuring a facility and staff ; Genentech's human insulin project ; The Eli Lilly contract ; Publicity and expansion -- 5. Human growth hormone: shaping a commercial future ; Competing for human growth hormone ; Moving toward corporate integration ; Scaling up insulin and growth hormone ; Corporate expansion ; An emerging culture -- 6. Wall Street debut ; Biomania ; Exit strategies ; Interferon: the new wonder drug? ; Run-up to an initial public offering ; Legal impediments ; The IPO.
610 20 $aGenentech, Inc.$xHistory.
650 0 $aBiotechnology industries$zUnited States$xHistory.
650 0 $aBiotechnology$xHistory.
830 0 $aSynthesis (University of Chicago. Press)
907 $a.b24916390$b12-20-18$c01-18-12
998 $a(2)xbt$axsf$am2$b03-05-12$cm$da $e-$feng$gilu$h0$i12
957 00 $aOCLC reclamation of 2017-18
907 $a.b24916390$b08-13-15$c01-18-12
956 $aPre-reclamation 001 value: ocn701242603
980 $a0212 KL
998 $a(2)xbt$axsf$am2$am6$b03-05-12$cm$da$e-$feng$gilu$h0$i12
994 $aC0$bSFR
999 $yMARS
945 $a338.766$bH8747g$d - - $e05-03-2018 16:55$f0$g0$h07-25-18$i31223098606628$j501$0800$k - - $lxbtci$o-$p$25.00$q-$r-$s- $t0$u13$v21$w0$x2$y.i6840329x$z03-08-12
945 $a338.766$bH8747g$d - - $e02-25-2018 15:56$f0$g0$h03-18-18$i31223098606610$j191$0191$k - - $lxbtci$o-$p$25.00$q-$r-$sm $t0$u13$v18$w0$x2$y.i68403306$z03-08-12
945 $a338.766$bH8747g$d - - $e - - $f0$g0$h - - $i31223098606636$j0$00$k - - $lxsfst$o-$p$25.00$q-$r-$so $t0$u0$v0$w0$x0$y.i68403288$z03-08-12
945 $a338.766$bH8747g$d - - $e09-29-2018 11:39$f0$g0$h11-20-18$i31223098606602$j241$0800$k - - $lm2aaa$ol$p$25.00$q-$r-$s- $t0$u24$v29$w1$x5$y.i68403318$z03-08-12